Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Prestigious Medical and Public Health Journal THE LANCET Regional Health Publishes Pivotal Phase 3 Clinical Study on Miqnaf® (Nafithromycin) A Landmark for India s Antibiotic Innovation .
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.6 pts less than Nifty Smallcap 250 and 5.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wockhardt announced that The Lancet Regional Health Southeast Asia, a peer-reviewed medical journal, has published the full Phase 3 clinical study results of Miqnaf® (nafithromycin), a novel antibiotic for treating community-acquired bacterial pneumonia (CABP). This is the first-ever publication in a Lancet journal for a novel drug discovered and developed in India. The Phase 3 trial, conducted in nearly 500 patients, showed Miqnaf® was non-inferior to moxifloxacin, with over 90% of patients showing clinical improvement within 3-4 days. Miqnaf® is the first new macrolide antibiotic in over 30 years, offers a once-daily, three-day oral regimen, and already holds Qualified Infectious Disease Product (QIDP) designation from the US FDA.
The high-profile Lancet publication strengthens global scientific credibility for Miqnaf® and Wockhardt's antibiotic pipeline, potentially supporting future US FDA approval efforts and international market expansion. This is a positive reputational milestone, though it does not directly translate to immediate revenue impact. Wockhardt derives ~77% of revenues from international businesses, so global recognition could support long-term growth in its pharma segment.